by Plus Therapeutics | Sep 17, 2025 | GBM, PBC
Each September, Childhood Cancer Awareness Month (#CCAM) serves as a powerful reminder to honor children and families affected by pediatric cancer and to raise awareness for the urgent need for new treatment options. At Plus Therapeutics (Nasdaq: PSTV), we are deeply...
by Plus Therapeutics | Aug 7, 2025 | GBM
Glioblastoma (GBM) is one of the most aggressive and challenging forms of brain cancer, with limited treatment options available today. At Plus Therapeutics (NASDAQ: PSTV), we are committed to developing new therapies that can bring hope to patients and their...
by Plus Therapeutics | Jul 22, 2025 | GBM
Each year on World Brain Day, the World Federation of Neurology (WFN) shines a global spotlight on the importance of brain health and the burden of neurological disorders. In 2025, this important observance carries the theme “Brain Health for All Ages”,...
by Plus Therapeutics | Jul 16, 2025 | GBM
As we continue to honor GBM Awareness Day, Plus Therapeutics is proud to spotlight new insights from our RESPECT-GBM Phase 2 clinical trial—research aimed at addressing the urgent need for better treatment options for patients with recurrent glioblastoma (GBM). In a...
by Plus Therapeutics | Jul 16, 2025 | GBM
Today marks GBM Awareness Day, an important opportunity to raise awareness about glioblastoma (GBM)—an aggressive and life-threatening brain cancer that continues to pose significant challenges for patients, families, and clinicians worldwide. At Plus Therapeutics, we...
by Plus Therapeutics | Jun 16, 2025 | GBM
We are proud to highlight one of Plus Therapeutics’ leading Principal Investigators, Andrew Brenner, M.D., Ph.D., who recently appeared on KABB News to speak with Melissa Vega about the challenges and advancements in treating glioblastoma (GBM) — one of the most...
Recent Comments